Publication

Article

Oncology Live®

Vol. 20/No. 20
Volume20
Issue 20

ASCO Survey: E-Cigarettes Are Widely Misperceived as Harmless Among Young Adults

Author(s):

Findings from a national survey show that vaping is not only more common but also more favorably perceived among younger age groups than older adults.

lung cancer

lung cancer

Findings from a national survey show that vaping is not only more common but also more favorably perceived among younger age groups than older adults, with 1 in 4 young people indicating their belief that vapes are “harmless” and not addictive.

Conducted by the American Society of Clinical Oncology (ASCO), the National Cancer Opinion Survey collected responses from 4001 individuals ≥18 years and organized answers by age group: Generation Z (18-22 years), millennials (23-28 years), Generation X (39-54 years), Baby Boomers (55-72 years), and the Silent Generation (≥73 years). ASCO asked respondents to say whether they agree or disagree with each of the following statements: “Flavored e-cigarettes are less damaging to your health than nonflavored e-cigarettes”; “You can’t get addicted to e-cigarettes”; and, “E-cigarettes are harmless.”

Millennials had the highest rates of accordance with each of the claims across all age groups, followed closely by Generation Z respondents. At 24% and 20%, respectively, millennials and Generation Z were more likely to agree that e-cigarettes are harmless (Figure). Further, 22% of Generation Z participants and 24% of millennials agreed that e-cigarettes are not addictive. Additionally, 27% and 29%, respectively, felt flavored vapes were less deleterious than their nonflavored counterparts. Those ≥39 years were less likely to hold these misconceptions, the ASCO survey said.

Responses showed that roughly 1 in 5 young adults uses e-cigarettes routinely or recreationally, despite the US Surgeon General’s warning that the products contain addictive and potentially harmful elements. Millenials (21%), Generation Z (18%), and Generation X (15%) had the highest rates of regular e-cigarette use, whereas only 1% of the Silent Generation and 5% of Baby Boomers said they smoked e-cigarettes every day. Overall, 1 in 8 Americans (13%) routinely smoke e-cigarettes.

The poll was conducted from July 9 to August 10, 2019. It notably predated the CDC’s investigation into severe e-cigarette—associated respiratory illnesses and subsequent deaths, initiated on August 17.

Figure. Rates of Agreement With Survey Statements

As of August 10, 71% of Americans supported FDA regulation of e-cigarettes.

National survey reveals one in five young adults regularly uses e-cigarettes and believes they are harmless, not addictive. ASCO. Posted online September 24, 2019. Accessed October 18, 2019. bit.ly/2mXLmPx.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.